Citations

Clear

108 citation(s) found for "Sheth, S".

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors
Nelson, Blessie Elizabeth , Jankú, Filip , Fu, Siqing , Dumbrava, Ecaterina E. , Hong, David S. , Karp, Daniel D. , Naing, Aung , Tsimberidou, Apostolia M. , Murthy, Ravi , Sheth, Rahul A. , Amaria, Rodabe N. , Carapanceanu, Nicoleta, Singh, Mahendra Pal , Carapanceanu, Valentin, Pezeshki, Abdulmohammad , Leontovich, Alexey A. , Kreider, Brent L. , Tung, David, Varterasian, Mary , Khazaie, Khashayarsha , Piha‐Paul, Sarina A. , Rodon, Jordi , Tsimberidou, Apostolia Maria , Murthy, Ravi , Sheth, Rahul A , Amaria, Rodabe N , Conley, Anthony P , Damodaran, Senthil , Raghav, Kanwal P S , Carapanceanu, Nicoleta , Singh, Mahendra Pal , Carapanceanu, Valentin , Pezeshki, Abdulmohammad , Kreider, Brent , Tung, David , Varterasian, Mary , Khazaie, Khashayarsha , Piha-Paul, Sarina A , Hong, David S , Conley, Anthony P. , Raghav, Kanwal

Mayo Clinic

Clinical Cancer Research | July 11, 2025 | Volume: 31 | Issue: 18 | Pages: 3864-3875

10.1158/1078-0432.ccr-24-3952 | PMID 40643985 Get It

Abstract Purpose: Intratumoral injection of Clostridium novyi-nontoxic (C. novyi-NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi-NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi-NT injection (day 8) across four dose cohorts (3 × 104 to 100 × 104 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 104C.novyi-NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi-NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.
Petechial hemorrhage in mechanical thrombectomy for distal and medium-vessel occlusions: technical considerations and outcomes
Baker, Amanda , Adeeb, Nimer , Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Cancelliere, Nicole M., Fiehler, Jens, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Yedavalli, Vivek , Stracke, Christian Paul , Shaikh, Hamza, Liebeskind, David S., Alexandre, Andrea , Faizy, Tobias D., Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Altschul, David , _, _, Amllay, Abdelaziz, Gopinathan, Anil, Dusart, Anne , Capirossi, Carolina , Mounayer, Charbel, Hsieh, Cheng-Yang, Stapleton, Christopher J. , Bellante, Flavio, Shaikh, Hamza , Cuellar-Saenz, Hugo H., Rabinov, James D. , Berge, Jérôme , Martinez-Gutierrez, Juan Carlos, Premat, Kévin , Chervak, Lina , Elhorany, Mahmoud, Quintero‐Consuegra, Miguel , Kan, Peter , Khandelwal, Priyank , Kadirvel, Ramanathan , Dofuku, Shogo , Nedelcu, Simona, Tjoumakaris, Stavropoula I, Barreau, Xavier, Liebeskind, David S. , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Gonzalez, Nestor R , Regenhardt, Robert W , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Essibayi, Muhammed Amir , Salim, Hamza , Fazzari, Melissa J. , Khatri, Deepak , Baker, Amanda, Musmar, Basel , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil A , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Aziz, Yasmin , Radu, Răzvan Alexandru , Klein, Piers , Ota, Takahiro , Mowla, Ashkan , Naamani, Kareem El , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Hecker, Constantin , Marnat, Gaultier , Griessenauer, Christoph J. , Pedicelli, Alessandro , Faizy, Tobias D. , Mendes Pereira, Vitor , Dmytriw, Adam A. , _, _, Amllay, Abdelaziz , Vagal, Achala , Schiphorst, Adrien ter , Thomas, Ajith J , Mounayer, Charbel , Weyland, Charlotte S. , Hsieh, Cheng‐Yang , Forestier, Géraud , Cuellar, Hugo , Valente, Iacopo , Sibon, Igor , Jesser, Jessica , Martinez-Gutierrez, Juan Carlos , Meyer, Lukas , Elhorany, Mahmoud , Aziz‐Sultan, Mohammad Ali , Killer-Oberpfalzer, Monika , Khandelwal, Priyank , Fahed, Robert , Salazar‐Marioni, Sergio , Nedelcu, Simona , Tjoumakaris, Stavropoula , Saleme, Suzana , Barreau, Xavier

Mayo Clinic

Journal of Neurosurgery | July 4, 2025 | Volume: 143 | Issue: 6 | Pages: 1501-1513

10.3171/2025.3.jns243030 | PMID 40614268 Get It

OBJECTIVE Mechanical thrombectomy (MT) is well established for large-vessel occlusion (LVO) strokes, but its safety in distal and medium-vessel occlusions (DMVOs) requires further investigation. This study analyzed the relationship between procedural approaches, petechial hemorrhage (PetH), and clinical outcomes in DMVO thrombectomy, with particular attention to technical considerations and the complex interplay between tissue injury and hemorrhagic complications. METHODS A retrospective cohort study was conducted on DMVO stroke patients treated with MT at 37 stroke centers worldwide from 2016 to 2024. Patients were categorized based on follow-up imaging into those with or without PetH. Four logistic regression models analyzed the association of PetH with favorable functional outcomes (modified Rankin Scale score ≤ 2) at 90 days, early neurological improvement (≥ 4-point National Institutes of Health Stroke Scale score decrease at 24 hours), all-cause mortality, and independent determinants of PetH. Adjusted odds ratios (aORs), 95% confidence intervals, and p values were reported. RESULTS Of 1428 patients, 439 (30.7%) developed PetH. Factors independently associated with PetH were multiple thrombectomy passes (aOR 1.58, 95% CI 1.21–2.06; p = 0.001), IV thrombolysis (aOR 1.31, 95% CI 1.01–1.69; p = 0.04), and the combined use of a stent retriever with aspiration as the first-line method compared with aspiration alone (aOR 1.66, 95% CI 1.15–2.38; p = 0.007). Conversely, general anesthesia (aOR 0.55, 95% CI 0.40–0.77; p < 0.001), higher Alberta Stroke Program Early CT Scores (aOR 0.76, 95% CI 0.69–0.83; p < 0.001), and successful recanalization (aOR 0.56, 95% CI 0.39–0.80; p = 0.002) were significantly associated with a lower odds of PetH. PetH was associated with a decreased odds of favorable functional outcomes (aOR 0.51, 95% CI 0.36–0.73; p < 0.001), reduced early neurological improvement (aOR 0.59, 95% CI 0.44–0.79; p < 0.001), and increased all-cause mortality (aOR 1.84, 95% CI 1.23–2.76; p < 0.001). CONCLUSIONS PetH is a frequent sequela following MT in DMVO strokes and is associated with poorer outcomes, likely reflecting underlying ischemic injury rather than direct causation. Procedural factors influence PetH risk, suggesting medical treatment as first-line therapy for DMVOs, with MT reserved for refractory cases using less aggressive approaches.
BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023
Kazerooni, Anahita Fathi , Khalili, Nastaran, Liu, Xinyang , Jiang, Zhifan , Pavaine, Julija , Jones, Blaise V. , Sheth, Nakul , McAllister, Aaron S. , Tu, Wenxin , Rodriguez, Andres Fernandez, Shaikh, Ibraheem S , Sanchez-Montano, Mariana , Lai, Hollie Anne , Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammed, Aristizábal, Alejandro , Baid, Ujjwal , Bergquist, Timothy , Conte, Gian-Marco, Eddy, James A. , Ezhov, Ivan , Gandhi, Deep , Gottipati, Anurag , Haldar, Shuvanjan, Janas, Anastasia , Elaine, Elaine, Karargyris, Alexandros , Kassem, Hasan, Khalili, Neda , Maleki, Nazanin , Meier, Zeke, Saluja, Rachit , Sheller, Micah , Shinohara, Russell Takeshi, Viswanathan, Karthik , Wang, Chunhao , Storm, Phillip B. , Packer, Roger, Hummel, Trent R. , Hoffman, Lindsey M. , Nabavizadeh, Ali , Ware, Jeffrey B., Rood, Brian , Resnick, Adam J., Linguraru, Marius George , Khalili, Nastaran, Haldar, Debanjan , Zapaishchykova, Anna , Shah, Lubdha M. , Prabhu, Sanjay P. , Nandolia, Khanak , Anderson, Hannah, Bagheri, Sina , Borja, Austin J. , Calabrese, Evan , Chung, Verena , Familiar, Ariana , Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Moawad, Ahmed W. , Pati, Sarthak , Piraud, Marie , Poussaint, Tina Young , Reitman, Zachary J. , Rudie, Jeffrey D. , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Davatzikos, Christos , Bornhorst, Miriam , Blank, Peter M K de , Aboian, Mariam , Kann, Benjamin H. , Bakas, Spyridon , Vossough, Arastoo

Mayo Clinic

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: June 2025 | Pages: 72-87

10.59275/j.melba.2025-f6fg Get It

Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTS-PEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.
APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban
Renedo, Daniela , Huo, Shufan, Gilmore, Emily J. , Falcone, Guido J. , Clocchiatti‐Tuozzo, Santiago , Rivier, Cyprien , Huo, Shufan , Havenon, Adam de , Hawkes, Maximiliano A. , Schwamm, Lee H. , Sheth, Kevin N. , Gill, Thomas M.

Mayo Clinic

JAMA Neurology | June 23, 2025 | Volume: 82 | Issue: 8 | Pages: 808

10.1001/jamaneurol.2025.0182 | PMID 40549373 Get It

Importance The APOE ε4 variant is causally linked to cerebral amyloid angiopathy and is a risk factor for intracranial hemorrhage (ICH) among warfarin-treated patients with atrial fibrillation. Nevertheless, its impact on those treated with apixaban remains unknown. Objective To test the hypothesis that APOE ε4 allele carriership is associated with an increased risk of ICH in patients with atrial fibrillation taking apixaban. Design, Setting, and Participants This cohort study involved data from the All of Us Research Program, a longitudinal, population-based study in the United States. Inclusion criteria were age older than 50 years, history of atrial fibrillation, and anticoagulation with apixaban. Participants with a history of ischemic stroke or ICH were excluded. Up to 3 years of follow-up data were available. Data were collected from 2017 to 2022 and analyzed from November 2023 to December 2024. Exposure APOE ε2, ε3, and ε4 were ascertained using variants rs429358 and rs7412. APOE ε4 was modeled dichotomously (noncarriers [no alleles] vs carriers [1 or 2 alleles]). Main Outcomes and Measures Incident ICH, including any new intraparenchymal, subdural, or subarachnoid hemorrhage after initiation of apixaban therapy. Results Of 413 477 All of Us participants, 2038 were eligible. Their mean (SD) age was 71 (9) years; 918 (45%) were female, 1120 (55%) were male, and 1710 (83%) had European ancestry. Among these participants, 483 (23.7%) were carriers of at least 1 APOE ε4 allele. After a median follow-up of 2.9 years, 26 participants sustained an ICH (cumulative incidence, 1.5%; 95% CI, 1.0%-2.2%), of whom 12 (cumulative incidence, 3.1%; 95% CI, 1.7%-5.3%) were carriers and 14 (cumulative incidence, 1%; 95% CI, 0.6%-1.7%) were noncarriers ( P = .007). Multivariable Cox proportional hazard models confirmed this association: compared with noncarriership, APOE ε4 carriership was associated with a 3-fold increase in the risk of ICH (hazard ratio, 3.07; 95% CI, 1.42-6.65). APOE information improved the discrimination of risk prediction scores (C statistic of 0.74 and 0.68 for models with and without APOE , respectively; P = .03). Conclusions and Relevance Further research is needed to evaluate whether cerebral amyloid angiopathy mediates the observed association and whether APOE e4 information improves clinical decision-making about anticoagulation therapy in patients with atrial fibrillation. The latter is important now that APOE information is used in clinical settings to guide antiamyloid treatment for Alzheimer disease and has been returned to millions of persons by direct-to-consumer genotyping companies.
Marine Microplastic Levels and the Prevalence of Cardiometabolic Diseases in US Coastline Counties
Makwana, Bhargav , Khadke, Sumanth , Kumar, Ashish , Nasir, Khurram , Wadhera, Rishi K. , Shah, Rikin , Sheth, Sudip , Kong, Yixin , Navas‐Acién, Ana , Rajagopalan, Sanjay , Al‐Kindi, Sadeer , Ganatra, Sarju , Wadhera, Rishi K , Al-Kindi, Sadeer , Dani, Sourbha S , Ganatra, Sarju , Kumar, Ashish , Adamkiewicz, Gary , Dani, Sourbha S. , Moffatt‐Bruce, Susan D.

Mayo Clinic

Journal of the American Heart Association | June 18, 2025 | Volume: 14 | Issue: 13 | Pages: No page available

10.1161/jaha.124.039891 | PMID 40528809 Get It

Background Although micro‐ and nanoplastics are an emerging risk factor for the development of cardiovascular diseases, the association of marine microplastic levels (MMLs) with the burden of cardiometabolic diseases at a population level remains unexplored. We investigated the relationship between the mean microplastic concentration in ocean water within 200 nautical miles of the US coastline and the prevalence of type 2 diabetes, coronary artery disease, and stroke in nearby counties. Methods Microplastic concentration data within 200 nautical miles of the US coastline were geospatially analyzed to calculate mean MMLs. The coastal counties were stratified into 4 categories based on MMLs in the adjacent ocean water body: low, medium, high, or very high. The Behavioral Risk Factor Surveillance System 2019 to 2020 survey data were used to identify the prevalence of type 2 diabetes, coronary artery disease, and stroke in these counties. Univariate and population‐weighted multivariate quasi‐Poisson regression, adjusted for county‐level confounding variables, was used to evaluate the unadjusted and adjusted associations between disease prevalence and MMLs. Results The mean age of the population was 43±6 years. After adjusting for age, sex, physician access, and socioenvironmental vulnerabilities at the county level, counties with very high MMLs exhibited an 18%, 7%, and 9% higher adjusted prevalence of type 2 diabetes, coronary artery disease, and stroke, respectively, compared with those with low levels. Conclusion Marine microplastic levels were significantly associated with the prevalence of cardiometabolic diseases in coastal counties. Comprehensive studies at an individual level are needed to further investigate the health impacts of microplastic pollution.
Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network
Sheth, Samip , Inestroza, Karla , Weber, Brittany , Garshick, Michael , Garshick, Michael , Inestroza, Karla , Weber, Brittany , Merola, Joseph F.

Mayo Clinic

Journal of Psoriasis and Psoriatic Arthritis® | May 28, 2025 | Volume: 10 | Issue: 4 | Pages: 124-130

10.1177/24755303251337020 | PMID 40454109 Get It

Patients with psoriasis (PsO) and psoriatic arthritis (PsA) are at significantly increased risk for cardiovascular (CV) disease, attributed to chronic systemic inflammation and a high burden of cardiometabolic comorbidities. Despite this, CV risk factors in this population are frequently underdiagnosed and undertreated. This consensus document, developed by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN), provides practical recommendations for dermatologists, rheumatologists, and primary care physicians to improve CV risk assessment and management in PsO and PsA. Key recommendations include conducting baseline CV risk assessments at diagnosis—particularly for patients with moderate-to-severe PsO, PsA, or those requiring biologic therapy—and routine screening for hypertension, diabetes, dyslipidemia, smoking, obesity, and metabolic syndrome. The use of biomarkers such as high-sensitivity C-reactive protein and lipoprotein(a) may help refine risk stratification. Patients at elevated risk should be referred to their primary care provider or a cardiologist for further evaluation and may require additional imaging, including coronary artery calcium scoring. Lifestyle counseling on diet, exercise, weight management, and smoking cessation is essential. Pharmacologic strategies, such as earlier initiation of statins and consideration of glucagon-like peptide-1 (GLP-1) receptor agonists, are encouraged when clinically appropriate. Systemic inflammation should be reduced using anti-inflammatory therapies, although outcome data remain mixed. Clinicians must carefully assess the risks and benefits of NSAIDs, corticosteroids, and Janus kinase (JAK) inhibitors. This document aims to bridge existing gaps in interdisciplinary care and facilitate earlier, more aggressive CV risk management in psoriatic disease, aligning with current cardiology and dermatology guidelines to reduce morbidity and mortality.
Long‐Term Impact of GLP‐1 Receptor Agonists on AF Recurrence After Ablation in Obese Patients
Patel, Harsh , Sheth, Aakash , Nair, Ambica , Patel, Bhavin , Narasimhan, Bharat , Mehta, Nishaki , Asad, Zain Ul Abideen , Kowlgi, Gurukripa N. , DeSimone, Christopher V. , Siontis, Konstantinos C. , Labedi, Mohamed, Deshmukh, Abhishek , Mehta, Nishaki , Asad, Zain Ul Abideen , Kowlgi, Narayan G , DeSimone, Christopher V , Deshmukh, Abhishek J , Patel, Bhavin A , Sheth, Aakash R , Thakkar, Samarthkumar , Dani, Sourbha S.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 23, 2025 | Volume: 36 | Issue: 8 | Pages: 1808-1816

10.1111/jce.16737 | PMID 40406931 Get It

ABSTRACT Background Obesity is an important risk factor associated with atrial fibrillation (AF). The impact of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on recurrent AF among patients undergoing catheter ablation is not well described. Objective This study aimed to evaluate the effect of GLP‐1 RA on the recurrence of AF among obese patients after catheter ablation. Methods Utilizing the TriNetX research network, we identified patients aged over 18 with obesity (BMI ≥ 30) who underwent AF ablation from January 1, 2015, to December 1, 2022, using Current Procedural Terminology codes. Patients were categorized based on their baseline GLP‐1 RA use. Through propensity‐score matching, each cohort comprised 1558 patients. The primary outcome encompassed a composite of cardioversion, initiation of new antiarrhythmic drug (AAD) therapy, or redo AF ablation. Additional outcomes during the 12‐month follow‐up included AF readmission, heart failure readmissions, readmissions due to ischemic stroke, and mortality, with a separate analysis done for patients with BMI > 40. Results GLP‐1 RA use in patients with obesity undergoing AF ablation was linked to a significantly reduced risk of cardioversion, new AAD therapy, and the need for redo AF ablation (hazard ratio [HR] 0.72 [0.65–0.80]; p < 0.001). At 12 months, individuals on GLP‐1 agonists exhibited a lower likelihood of mortality (HR 0.61 [0.40–0.93]; p < 0.001). Although all other secondary outcomes were lower in the GLP‐1 RA group, there was no significant difference in ischemic stroke between the groups. These results were consistent among patients with BMI > 40, although apart from ischemic stroke, there was no difference in mortality between the two groups. Conclusion The utilization of GLP‐1 RA in individuals with obesity is linked to a decreased likelihood of arrhythmia recurrence following AF ablation, leading to a reduced requirement for cardioversion, AAD therapy, or redo AF ablation.
A multicenter, propensity score-matched analysis of functional outcomes and recanalization success with or without Trevo for Medium and distal vessel occlusion
Siegler, James E. , Koneru, Manisha , Shaikh, Hamza, Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Tjoumakaris, Stavropoula , Henninger, Nils , Sundararajan, Sri Hari , Tan, Benjamin Yong‐Qiang , Heit, Jeremy J , Regenhardt, Robert W. , Kass‐Hout, Tareq , Fiehler, Jens, Puri, Ajit S , Dyzmann, Christian , Barreau, Xavier, Renieri, Leonardo, Filipe, João Pedro , Harker, Pablo, Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric, Abdalkader, Mohamad , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus A, Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Khalife, Jane, Rana, Ankit, Guenego, Adrien , Investigators, for the MAD MT, Heit, Jeremy J. , Salim, Hamza , Tjoumakaris, Stavropoula , Henninger, Nils , Kühn, Anna Luisa , Ghozy, Sherief , Scarcia, Luca , Regenhardt, Robert W , Morsi, Rami Z , Vigilante, Nicholas , Rouchaud, Aymeric , Essibayi, Muhammed Amir , Dyzmann, Christian , Colasurdo, Marco , Filipe, João Pedro , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Klein, Piers , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Griessenauer, Christoph J , Liebeskind, David S. , Tancredi, Illario , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Yedavalli, Vivek S , Siegler, James E , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Daraghma, Motaz , Kühn, Anna Luisa , Ghozy, Sherief , Morsi, Rami Z. , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Sheth, Sunil A , Essibayi, Muhammed Amir , Colasurdo, Marco , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Clarençon, Frédéric , Klein, Piers , Nguyen, Thanh N. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Mendes Pereira, Vitor , Khalife, Jane , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

Interventional Neuroradiology | May 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251341603 | PMID 40398470 Get It

Background Endovascular therapy (EVT) for stroke due to distal or medium vessel occlusion (DMVO) is safe. Due to the distinct anatomical characteristics of DMVOs, further evaluation of EVT is crucial to determine which devices may yield better outcomes. Methods A retrospective analysis of adults with DMVO treated in 37 centers (11 countries) was queried. The primary outcome of favorable shift in 90-day modified Rankin Scale (mRS) was compared between patients treated with Trevo versus other devices on first pass using 1:1 propensity score matching (PSM) with multivariable adjustment. Secondary outcomes included the number of pass attempts, final thrombolysis in cerebral infarction (TICI) score 2b-3, symptomatic intracranial hemorrhage (sICH), improvement in National Institutes of Health Stroke Scale (NIHSS) at 24h, and 90-day mortality. Results Of the 1115 included patients, 264 (24%) were treated with Trevo (PSM cohort of 261 per group). Trevo use was not associated with a favorable 90-day mRS shift (proportional odds ratio [OR] 1.10, 95% confidence interval [CI] 0.80–1.51). Trevo was associated with fewer passes (adjusted β=-0.25, 95% CI −0.48 - −0.03), higher odds of TICI 2b-3 (adjusted OR 1.97, 95% CI 1.11–3.49), and a greater 24h NIHSS improvement (adjusted β= −1.74, 95% CI −3.11 - −0.36), with no difference in sICH or mortality (p>0.05). Results were similar in sensitivity analyses. Conclusions We observed no safety concerns with Trevo as compared to other EVT devices for DMVO recanalization. There was a signal of better technical efficacy and early clinical improvement.
Higher risk of recurrence in partially thrombosed cerebral aneurysms post-WEB (Woven EndoBridge) device treatment: insights from the WorldWideWEB Consortium registry
Saliou, Guillaume , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Aslan, Assala , Swaid, Christian, Cuellar, Miguel, Dibas, Mahmoud , Cancelliere, Nicole M , Diestro, Jose Danilo Bengzon , Lay, Sovann V. , Guenego, Adrien , Möhlenbruch, Markus , Kral, Michael , Salem, Mohamed M , Foreman, Paul M. , Shaikh, Hamza , Župančić, Vedran , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios‐Nikos , Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan Karl, Slawski, Diana , Pulli, Benjamin , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Haranhalli, Neil , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Jabbour, Pascal , Clarençon, Frédéric , Patel, Aman B. , Salim, Hamza , Ghozy, Sherief , Lay, Sovann V , Guenego, Adrien , Carnevale, Joseph Anthony , ElNaamani, Kareem , Shotar, Eimad , Chung, Charlotte , Salem, Mohamed M , Lylyk, Ivan , Shaikh, Hamza A , Hafeez, Muhammad U , Catapano, Joshua S , Ren, Yifan , Schirmer, Clemens M , Michelozzi, Caterina , Hassan, Ameer E , Ogilvie, Mark , Nguyen, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Huynh, Thien J, Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A , Tawk, Rabih G , Pulli, Benjamin , Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Levy, Elad I , Albuquerque, Felipe C , Stapleton, Christopher , Kan, Peter , Kalousek, Vladimir , Tjoumakaris, Stavropoula , Cuellar-Saenz, Hugo H , Jabbour, Pascal , Dmytriw, Adam A , Hajdu, Steven D , Dibas, Mahmoud , Diestro, Jose Danilo B , Saliou, Guillaume , Altschul, David J , Musmar, Basel , Regenhardt, Robert W , Cancelliere, Nicole M , Ulfert, Christian , Burkhardt, Jan‐Karl , Cuellar, Miguel, Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Lylyk, Iván , Hafeez, Muhammad Ubaid , Waqas, Muhammad , Arslan, Muhammet , Ergün, Onur , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Huynh, Thien , Essibayi, Muhammed Amir , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Levy, Elad I. , Cuellar, Hugo , Limbucci, Nicola , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | April 30, 2025 | Volume: 18 | Issue: 3 | Pages: 782-789

10.1136/jnis-2024-022628 | PMID 40306928 Get It

Background The Woven EndoBridge (WEB) device is a prevalent treatment for intracranial aneurysms. While many studies have assessed the obliteration rate post-WEB embolization, few have focused on long-term outcomes in partially thrombosed aneurysms. Objective To assess whether partially thrombosed aneurysms are at higher risk of recurrence or retreatment following WEB embolization compared with non-thrombosed aneurysms. Methods We evaluated data from 22 academic institutions, focusing on previously untreated cerebral aneurysms treated with the WEB device. Logistic regression was utilized to analyze factors predicting long-term aneurysm obliteration and retreatment necessity. Results Among 1303 patients, 26 presented with a partially thrombosed aneurysm. In the partially thrombosed group, the mean aneurysm maximal diameter was 10.7±4 mm with a neck ratio of 1.99±1.19 mm, larger than in the control group where the mean aneurysm maximal diameter was 6.81±2.37 mm with a neck ratio of 1.64±0.51 mm (P<0.001 for both maximal diameter and neck ratio). At the final follow-up, partially thrombosed aneurysms treated by the WEB device had a 38.5% retreatment rate, compared with 7.0% for non-thrombosed aneurysms (P<0.001). Among partially thrombosed aneurysms, the Raymond-Roy type IIIa/b occlusion rate was higher (38.5% vs 9.9%, P<0.001). On multivariate analysis, partially thrombosed aneurysms compared with non-thrombosed aneurysms had an increased rate of retreatment (OR 3.64, 95% CI 1.28 to 10.1). Conclusion Partially thrombosed aneurysms are associated with a poorer occlusion rate and a higher rate of retreatment following WEB embolization. For partially thrombosed aneurysms, the WEB device appears suboptimal as a first-line treatment, and therefore alternative techniques should be prioritized.
Using Large-scale Contrastive Language-Image Pre-training to Maximize Brain MRI-Based Headache Classification (P4-12.007)
Rafsani, Fazle , Sheth, Devam, Che, Yiming , Shah, Jay , Nikolva, Simona, Sheth, Devam, Siddiquee, Md Mahfuzur Rahman , Chong, Catherine D. , Dumkrieger, Gina , Li, Baoxin , Wu, Teresa , Schwedt, Todd J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210540 Get It